AusBiotech’s biotech and medtech members are being invited to complete the organisation’s first annual AusBiotech Voice on Investment Survey.
The Survey seeks critical member insights as AusBiotech builds new strategies and programs to help bridge the gap between investor and company needs in the Australian biotech ecosystem.
According to the Beyond Borders: EY Biotechnology Report 2024, the biotech sector’s market size is projected to reach US$1.2 trillion by the end of 2024, while Grand View Research projects the market to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030 to a US$3.88 trillion market.
The market is driven by continued innovation and strong clinical pipelines, increased dealmaking and a recovery in the financing environment as well as government support and a rising demand from population needs in areas such as personalised medicine and rare diseases.
Despite the strong market growth, it is well recognised that biotech firms encounter various obstacles when trying to attract investment due to the complex nature of the lifesciences industry. Simultaneously, the availability of capital and investor confidence can be impacted by fluctuations in the world financial markets. When investors are looking to invest in biotech companies, they examine the underlying science and technology, gauging the research's robustness, scalability, and proof of concept as well as the company's commercialisation strategy and the experience and performance history of the management team. With all these factors in play, finding investor-investee synergy can be challenging, but is possible as shown by a number of Australian success stories.
AusBiotech is considering new strategies to help bridge the gap between investor and company needs in the Australian biotech ecosystem. Our goal will be to enable greater synergies between these groups and help accelerate the path to commercialisation for our biotech and medtech members. We are now gathering insights to ensure this work is evidence led.
Complete the AusBiotech Voice on Investment Survey
If you are a biotech or medtech company leader who has sought, is seeking, or plan to seek investment, please click this link to complete AusBiotech’s Voice on Investment Survey by Tuesday, 15 October 2024.
All responses will be deidentified and aggregated for analysis. If you have any queries, please contact AusBiotech’s Global Investment Lead, Rhenu Bhuller at rbhuller@ausbiotech.org.